HOSPIRA INC - FORM 8-K - EX-99.1 - February 2, 2011

Attached files

file filename
8-K - 8-K - HOSPIRA INCa11-4903_18k.htm

 

Exhibit 99.1

 

Hospira, Inc.

Net Sales by Product Line

(Unaudited)

(dollars in millions)

 

 

 

Year Ended December 31,

 

 

 

2010

 

2009

 

2008

 

Americas—

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

$

1,829.0

 

$

1,589.9

 

$

1,328.9

 

Medication Management (1)

 

827.5

 

917.0

 

927.4

 

Other Pharma

 

481.4

 

556.4

 

522.0

 

Total Americas

 

3,137.9

 

3,063.3

 

2,778.3

 

 

 

 

 

 

 

 

 

Europe, Middle East & Africa—

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

283.2

 

272.0

 

287.4

 

Medication Management (1)

 

126.6

 

142.4

 

144.3

 

Other Pharma

 

78.7

 

128.4

 

152.1

 

Total Europe, Middle East & Africa

 

488.5

 

542.8

 

583.8

 

 

 

 

 

 

 

 

 

Asia Pacific—

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

237.3

 

211.4

 

205.4

 

Medication Management (1)

 

45.0

 

45.4

 

46.8

 

Other Pharma

 

8.5

 

16.4

 

15.2

 

Total Asia Pacific

 

290.8

 

273.2

 

267.4

 

 

 

 

 

 

 

 

 

Net Sales

 

$

3,917.2

 

$

3,879.3

 

$

3,629.5

 

 

 

 

 

 

 

 

 

Global—

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

$

2,349.5

 

$

2,073.3

 

$

1,821.7

 

Medication Management (1)

 

999.1

 

1,104.8

 

1,118.5

 

Other Pharma

 

568.6

 

701.2

 

689.3

 

 

 

 

 

 

 

 

 

Net Sales

 

$

3,917.2

 

$

3,879.3

 

$

3,629.5

 

 

(1) As part of Project Fuel, Hospira disposed of the non-strategic critical care business, during 2009. As a result, the former Other Devices product line is now included in a single device product line, Medication Management.  Medication Management includes infusion pumps, related software and services, dedicated administration sets, gravity administration sets, critical care products (through August 2009) and other device products.

 


 

Hospira, Inc.

Net Sales by Product Line

(Unaudited)

(dollars in millions)

 

 

 

2010

 

2009

 

2008

 

 

 

Q4

 

Q3

 

Q2

 

Q1

 

Q4

 

Q3

 

Q2

 

Q1

 

Q4

 

Q3

 

Q2

 

Q1

 

Americas—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

$

458.7

 

$

433.4

 

$

453.0

 

$

483.9

 

$

439.2

 

$

449.1

 

$

368.5

 

$

333.1

 

$

347.2

 

$

341.1

 

$

299.9

 

$

340.7

 

Medication Management (1)

 

206.2

 

209.6

 

205.2

 

206.5

 

231.1

 

228.3

 

243.8

 

213.8

 

226.4

 

234.8

 

254.6

 

211.6

 

Other Pharma

 

114.0

 

119.1

 

122.9

 

125.4

 

153.2

 

126.0

 

139.4

 

137.8

 

147.6

 

129.8

 

122.7

 

121.9

 

Total Americas

 

778.9

 

762.1

 

781.1

 

815.8

 

823.5

 

803.4

 

751.7

 

684.7

 

721.2

 

705.7

 

677.2

 

674.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe, Middle East & Africa—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

77.7

 

68.3

 

67.3

 

69.9

 

76.7

 

69.6

 

68.1

 

57.6

 

63.2

 

67.5

 

78.4

 

78.3

 

Medication Management (1)

 

32.9

 

31.1

 

28.6

 

34.0

 

37.2

 

34.4

 

34.9

 

35.9

 

32.7

 

37.8

 

35.8

 

37.9

 

Other Pharma

 

18.4

 

16.8

 

24.9

 

18.6

 

39.7

 

25.6

 

35.4

 

27.7

 

31.9

 

41.3

 

42.4

 

36.6

 

Total Europe, Middle East & Africa

 

129.0

 

116.2

 

120.8

 

122.5

 

153.6

 

129.6

 

138.4

 

121.2

 

127.8

 

146.6

 

156.6

 

152.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asia Pacific—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

68.6

 

57.0

 

54.1

 

57.6

 

62.4

 

57.0

 

53.0

 

39.0

 

50.1

 

57.3

 

52.4

 

45.6

 

Medication Management (1)

 

13.0

 

12.0

 

10.4

 

9.6

 

11.4

 

11.7

 

11.1

 

11.2

 

11.5

 

11.4

 

11.9

 

12.0

 

Other Pharma

 

2.6

 

2.0

 

1.8

 

2.1

 

4.3

 

5.8

 

2.7

 

3.6

 

3.1

 

4.5

 

3.5

 

4.1

 

Total Asia Pacific

 

84.2

 

71.0

 

66.3

 

69.3

 

78.1

 

74.5

 

66.8

 

53.8

 

64.7

 

73.2

 

67.8

 

61.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

992.1

 

$

949.3

 

$

968.2

 

$

1,007.6

 

$

1,055.2

 

$

1,007.5

 

$

956.9

 

$

859.7

 

$

913.7

 

$

925.5

 

$

901.6

 

$

888.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Global—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Specialty Injectable Pharmaceuticals

 

$

605.0

 

$

558.7

 

$

574.4

 

$

611.4

 

$

578.3

 

$

575.7

 

$

489.6

 

$

429.7

 

$

460.5

 

$

465.9

 

$

430.7

 

$

464.6

 

Medication Management (1)

 

252.1

 

252.7

 

244.2

 

250.1

 

279.7

 

274.4

 

289.8

 

260.9

 

270.6

 

284.0

 

302.3

 

261.5

 

Other Pharma

 

135.0

 

137.9

 

149.6

 

146.1

 

197.2

 

157.4

 

177.5

 

169.1

 

182.6

 

175.6

 

168.6

 

162.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

992.1

 

$

949.3

 

$

968.2

 

$

1,007.6

 

$

1,055.2

 

$

1,007.5

 

$

956.9

 

$

859.7

 

$

913.7

 

$

925.5

 

$

901.6

 

$

888.7

 

 

(1) As part of Project Fuel, Hospira disposed of the non-strategic critical care business, during 2009. As a result, the former Other Devices product line is now included in a single device product line, Medication Management.  Medication Management includes infusion pumps, related software and services, dedicated administration sets, gravity administration sets, critical care products (through August 2009) and other device products.

 

Stock widget

Investing forum

HOSPIRA INC Reports